New River Pharmaceuticals Inc. Meets Enrollment In NRP104 Adult Phase III Study

RADFORD, Va., Sept. 12 /PRNewswire-FirstCall/ -- Presenting today at the Bear Stearns 19th Annual Healthcare Conference, New River Pharmaceuticals Inc. (Nasdaq: NRPH - News) announced that the enrollment numbers have been met for the company's NRP104.303 study, which will examine the safety and efficacy of NRP104 as a treatment for attention-deficit/hyperactivity disorder (ADHD) in adult populations (ages 18-52). Randal Kirk, New River's Chairman and CEO, and Krish Krishnan, CFO and COO, stated that the company expects to complete the study in Q4 2006, to announce top-line data in from the study in Q1 2007, and to file a supplemental new drug application for the adult indication in Q2 2007.